Advertisement Press Releases Archive - Page 137 of 231 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Pressreleases

  • Exco InTouch Joins Critical Path Institute ePRO Consortium to Advance Electronic Data Capture in Clinical Trials

    Exco InTouch, the leading provider of patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, today announced that it has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, a programme run by the Critical Path Institute (C-Path), which strives to enhance the quality of patient reported outcomes (PRO) in the evaluation of new pharmaceuticals.

  • Aptalis Pharmaceutical Technologies Announces European Commission Approval for a New Oral Granule Formulation of Viread®

    Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, today announced that the European Commission granted marketing authorization for a new pediatric indication of a new oral granule formulation of Gilead Sciences, Inc.'s Viread® (tenofovir disoproxil fumarate) for HIV-1 infected children aged 2 to less than 6 years, and for HIV-1 infected children above 6 years of age for whom a solid dosage form is not appropriate.

  • Aptalis Pharmaceutical Technologies Sponsors AAPS Research Achievement Awards in Pharmacokinetics, Pharmacodynamics and Drug Metabolism at AAPS Annual Meeting and Exposition

    Aptalis Pharmaceutical Technologies, formerly Eurand, focused on developing differentiated oral products utilizing its pharmaceutical technologies, today announces its sponsorship of the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Awards in Pharmacokinetics, Pharmacodynamics and Drug Metabolism and its participation in the 2012 AAPS Annual Meeting and Exposition October 14 – 18, 2012 in Chicago, Illinois.

  • PharmaTelevision Interview to Spotlight Aptalis Pharma’s Year in Review

    FDA approvals, revenue gain and organic business growth are just a few of the topics that John Fraher, President, Aptalis Pharma, addresses during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview, conducted during BIO 2012 in Boston, reflects Fraher’s commentary regarding the integration of companies post Axcan Intermediate Holdings’ acquisition of Eurand N.V. in 2011.

  • Aptalis Pharmaceutical Technologies Sponsors 2012 Controlled Release Society’s Young Investigator Award at Annual Meeting and Exposition

    Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that focuses on developing differentiated oral products utilizing its pharmaceutical technologies, today announces its co-sponsorship of Controlled Release Society’s Young Investigator Award and its participation in the 39th Annual Meeting & Exposition of the Controlled Release Society July 15 – 18, 2012 in Québec City, Canada.

  • Strength of Aptalis Pharmaceutical Technologies Patents Confirmed by AMRIX® Verdict

    Aptalis Pharmatech, Inc. (previously known as Eurand, Inc.) and Cephalon, Inc. a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit which reversed a lower court’s determination and held that two patents covering the AMRIX® muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.

  • CROMSOURCE upgrades to the new Oracle Clinical Release 4.6.4

    CROMSOURCE, a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions today announced successful completion of a project to upgrade their data management system to the new Oracle Clinical Release 4.6.4 (replacing version 4.5.3.).

  • Gyros Expands Asian Distribution to Singapore

    Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that Bio Laboratories Pte Ltd has become sole distributor for the company's nanoliter-scale immunoassay platform in Singapore.